Dany Habr has joined Pfizer Oncology as chief medical officer as of April 15.
Habr joins Pfizer from AbbVie where he served as their head of Oncology Global Medical Affairs, where he led launch readiness for medicines in hematology, lung and brain cancer indications. Prior to that he was the Global Clinical Development head for medicines to treat myelofibrosis, multiple myeloma, lung and breast cancer at Novartis.
“Dr. Habr’s experience is unparalleled in the industry and he has a strong passion for oncology. We are delighted to have him join the team as we continue on our path of developing the best possible treatment options for cancer patients,” Andy Schmeltz, Global President and General Manager, Pfizer Oncology, said in a statement.
Habr replaces Charles Hugh-Jones, who left Pfizer for Allergan last summer.
Earlier this year, Mace Rothenberg was promoted from his position as chief development officer, oncology, to chief medical officer.
